Several recent studies have focused on evaluating the anti-tumor effect of combined immunotherapy including cancer vaccine and ICIs, among which combinations of mAbs against human PD1 or PD-L1 were applied in conjunction with the clinically applied mAb Trastuzumab (34–38). This evidence concerns the gene CD274 and neoplasm.